From Jesus on YMB: CD16 (Moderate) and CD17 (Critical)
Vs CD12 (Severe/ Critical)
1. CD12 - Severe - CytoDyn, Dr. Bruce Patterson, Dr. Lalezari, Dr. seethmaraju, wanted 2 doses (1,400MG). The data gathered suggested that Leronlimab fades from the body day 7-10, with its peak being on day 3.
With the most powerful dose at 700MG, it allows the body to see the best results at the start, and then maintain the lower iL-6 and Rantes levels weekly with 350MG.
In order to get 4 doses for 28 days (presumed Homeostasis takes a month) they’re also adding an additional 350mg making it, 700, 350, 350, 350 = 1,800MG.
This likely prevents Cytokine Storm, saves the Hospital oxygen, ventilators, and perhaps prevents Long Haulers because it brings the body back into full homeostasis.
2. Why patients with pneumonia in CD16? The data suggests that’s who needs Leronlimab the most and when it shows it’s efficacy. If you recall, President Estrada’s Pneumonia, he was cleared, crediting Leronlimab via his son.
3. Patients (from my research) that have Pneumonia tend to be linked to Long Haulers. I would not one bit doubt that this data can also drive us to see if it can at least prevent Long Haulers; hence the 60 day study as well. Aka Clinical Status.
CD17 Critical
1. 2,800 MGs was the magic number we all felt we needed and now we got it. 1 week apart. This should help trends go to 86-92% survival improvement.
2. Intravenous = Quicker to the body. Older patients / geriatric patients need a faster response from the Paramedic / nurses and Doctors. Intravenous medication is the same. This helps the age stratification issue that the field will see in critical patients. 1 answer should fit all.
3. Trial size...NP explained 120 patients was all The “Hospital Israelita Albert Einstein” think was need needed based on the efficacy of this drug. To help expedite the P-Value I believe they more than doubled that number to achieve that P-Value via Interim Analysis so all the countries like MHRA, Brazil and maybe Philippines and India if they don’t give it an EUA before the trial ends.
Paraphrased the layout of: Comfortable_fan_8103 from Reddit
“if the trial starts by june 7, given 167 sites, we should get the 120 data by july 21;
now remember, these 120 are critical patients who received 4 serial doses of iv leronlimab.” -MGK
For now, ignore anything that doesn’t come from the company.
The trial is designed to have a statistically significant P-Value of .05 or better.
